These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30698142)

  • 1. Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
    Goldhamer DJ; Lees-Shepard JB
    Elife; 2019 Jan; 8():. PubMed ID: 30698142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
    Pacifici M; Shore EM
    Elife; 2019 Jan; 8():. PubMed ID: 30698141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
    Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
    Elife; 2018 Sep; 7():. PubMed ID: 30226468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
    Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
    BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
    Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
    J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palovarotene: First Approval.
    Hoy SM
    Drugs; 2022 Apr; 82(6):711-716. PubMed ID: 35384641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
    Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
    J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP).
    Lindborg CM; Brennan TA; Wang H; Kaplan FS; Pignolo RJ
    Bone; 2018 Apr; 109():153-157. PubMed ID: 28963080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
    Wentworth KL; Masharani U; Hsiao EC
    Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.
    Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M
    Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
    Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
    J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of progenitor cells that contribute to heterotopic skeletogenesis.
    Lounev VY; Ramachandran R; Wosczyna MN; Yamamoto M; Maidment AD; Shore EM; Glaser DL; Goldhamer DJ; Kaplan FS
    J Bone Joint Surg Am; 2009 Mar; 91(3):652-63. PubMed ID: 19255227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
    Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
    BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
    Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
    Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrodysplasia ossificans progressiva: a current review of imaging findings.
    Bauer AH; Bonham J; Gutierrez L; Hsiao EC; Motamedi D
    Skeletal Radiol; 2018 Aug; 47(8):1043-1050. PubMed ID: 29445932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
    Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
    J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.
    Rajapakse CS; Lindborg C; Wang H; Newman BT; Kobe EA; Chang G; Shore EM; Kaplan FS; Pignolo RJ
    Acad Radiol; 2017 Mar; 24(3):321-327. PubMed ID: 27989444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva.
    Wentworth KL; Bigay K; Chan TV; Ho JP; Morales BM; Connor J; Brooks E; Shahriar Salamat M; Sanchez HC; Wool G; Pignolo RJ; Kaplan FS; Hsiao EC
    Bone; 2018 Apr; 109():104-110. PubMed ID: 29033382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.